0.2748  -0.017 (-5.76%)		02-13 16:00
Open: 0.286 High: 0.307 Volume: 518,850		Pre. Close: 0.2916 Low: 0.2585 Market Cap: 15(M)

Short term
Mid term
Targets	6-month :	0.39	1-year :	0.45
Resists	First :	0.33	Second :	0.38
Pivot price	0.3
Supports	First :	0.25	Second :	0.21
MAs	MA(5) :	0.29	MA(20) :	0.31
	MA(100) :	0.48	MA(250) :	0.8
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	18.2	D(3) :	22.2
RSI	RSI(14): 37.1
52-week	High :	1.55	Low :	0.25

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ITRM ] has closed above bottom band by 3.6%. Bollinger Bands are 52.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.31 - 0.31	0.31 - 0.31
Low:	0.25 - 0.26	0.26 - 0.26
Close:	0.27 - 0.28	0.28 - 0.28

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Sat, 14 Feb 2026
Iterum Therapeutics expands Medicare Part D access for ORLYNVAH By Investing.com - Investing.com Australia

Fri, 13 Feb 2026
Iterum Therapeutics Provides Business Update - Bitget

Fri, 13 Feb 2026
Iterum Therapeutics Announces Expanded Market Access and Patent Protection for ORLYNVAH™ - Quiver Quantitative

Fri, 13 Feb 2026
Medicare to cover ORLYNVAH for 3.5M people, but FDA seeks new trial - Stock Titan

Wed, 17 Dec 2025
Iterum Therapeutics secures major PBM agreement for antibiotic - Investing.com

Wed, 17 Dec 2025
New PBM deal could open ORLYNVAH access to 40M more people in 2026 - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	53 (M)
Held by Insiders	5.237e+007 (%)
Held by Institutions	0.7 (%)
Shares Short	1,760 (K)
Shares Short P.Month	0 (K)

EPS	-1.932e+007
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	-1 %
Return on Assets (ttm)	982.3 %
Return on Equity (ttm)	-53.3 %
Qtrly Rev. Growth	390000 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	40559.4
Qtrly Earnings Growth	-0.8 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	-20 (M)

PE Ratio	-0.01
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	-5.24

Dividend	0
Forward Dividend	1.58e+006
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.